Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409596 | 1.00 | HRH3 (1.00) | HRH3KCNH2OPRD1KMT2ACYP1A2 | |
| SCHEMBL5218586 | 0.99 | HRH3 (0.98) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL14409481 | 0.99 | HRH3 (0.98) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL14409586 | 0.98 | HRH3 (0.96) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL5220599 | 0.98 | HRH3 (0.96) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL14409442 | 0.89 | HRH3 (0.80) | HRH3KCNH2OPRD1KMT2ACYP1A2 | |
| SCHEMBL5217787 | 0.89 | HRH3 (0.80) | HRH3KCNH2OPRD1KMT2ACYP1A2 | |
| SCHEMBL14409420 | 0.87 | HRH3 (0.78) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL5220654 | 0.87 | HRH3 (0.78) | HRH3KCNH2OPRD1KMT2A | |
| SCHEMBL14409440 | 0.87 | HRH3 (0.77) | HRH3KCNH2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474419-B1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK AS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-7101898-B2 | For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder | NOVO NORDISK A/S (DK) | 2006-09-05 | — | — | US | disclosed |
| EP-1474419-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-16 | — | — | US | disclosed |
| WO-2003064411-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HRH3, HRH2, HRH4 | HRH3 1/4885KCNH2 294/4885OPRD1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.